AC Immune (ACIU) announced that it will receive the second ReTain-related milestone payment, CHF 24.6 million, under its agreement with Janssen Pharmaceuticals, a Johnson & Johnson company (JNJ). The milestone payment has been triggered by the rapid rate of prescreening in the potentially registrational Phase 2b ReTain trial investigating active-immunotherapy candidate ACI-35.030 to treat preclinical Alzheimer’s disease. With last December’s milestone payment, this brings the total milestone payments received for ACI-35.030 related to this trial to CHF 40 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACIU:
- AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
- AC Immune’s Diagnostic Achieves FDA Fast Track Status
- FDA grants AC Immune’s PI-2620 Tau-PET diagnostic fast track designations
- AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
- AC Immune SA Announces $80M Open Market Sales Plan